Osteoporosis Therapeutics - A Global Market Perspective

Osteoporosis Therapeutics - A Global Market Perspective published by BizAcumen, Inc. in November, 2009. This report consists of Pages: 166 and the price starts from US $ 2995.

Introduction

Abstract

Osteoporosis, the most common type of metabolic bone diseases, is an implacable epidemic growing rapidly in regions of North America, Europe, and Japan. Afflicting millions of people across the world, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Major therapeutic classes currently available include bisphosphonates, Estrogen Replacement Therapy (ERT) drugs, calcitonins and Selective Estrogen Receptor Modulators (SERMs). Parathyroid Hormone (PTH)-based drugs comprise the most recent genre of therapeutics with new bone-forming potential. As osteoporosis is asymptomic, several cases of osteoporosis are detected only after experiencing a fracture.

These and other market data and trends are presented in "Osteoporosis Therapeutics: A Global Market Perspective" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Table of Contents

1. METHODOLOGY

• Study Reliability and Reporting Limitations
• Disclaimers
• Quantitative Techniques & Reporting Level

2. OUTLOOK

3. INDUSTRY OVERVIEW

• Osteoporosis Therapeutics: An Evolutionary Scan
• "A Sketch of the Present Industry Scenario"
• Facts & Figures: The Osteoporosis Primacy
  • Snapshots
• Factors Influencing Demand
• Competitive Landscape
• Market Trends and Issues
  • Can New Treatments Beat the Gold Standard?
  • Oral Calcitonin Likely to Emerge as Wonder Drug
  • New Bisphosphonates Challenge Established Brands
  • Side Effects of HRT Fuel Natural Alternatives Sales
  • Bone Formation Drugs Augur New Prospects
  • Estrogen Replacement Therapy: Will Dosing Make a Difference?
  • Is Prevention Always Better Than Cure?
  • Peptide-Based Osteoporosis Therapy Gaining Ground
  • Polymorphism- A Potent Diagnostic Marker
  • Bisphosphonates - The Other Side
  • Efficacy of Evista Under the Scanner

4. MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE

• ERT Drugs
  • Ups and Downs in the ERT Market
• Bisphosphonates
  • The leading Therapeutic Market
• SERMs (Selective Estrogen Receptor Modulators)
  • Market Overview
• Calcitonins
  • Market Overview

5. PRODUCT FACTS

• Bisphosphonates
• Hormone Replacement Therapy/ Estrogen Replacement Therapy
• Estrogens
• Estrogens/Progesterones
• Calcitonins
• Selective Estrogen Receptor Modulators (SERMs)
• Other Therapeutics

6. MAJOR CLINICAL TRIALS/FINDINGS

7. CORPORATE DEVELOPMENTS

• Schering-Plough Acquires Organon BioSciences
• Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline
• Alethia and Emerillon Collaborate on Osteoporosis Therapies
• Ipsen Enters into Co-marketing Agreement with MSD
• Unigene Enters into Agreement with Novartis
• Pharming Group Granted Subsidies to Develop Osteoporosis Drugs
• Procter & Gamble Terminates Nasal Spray Collaboration with Nastech- Pharmaceutical
• GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics
• Radius Initiates Phase II Trials for BA058
• Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon Calcitonin
• Medivir Initiates First Human Trials for MIV-701
• P&G Receives FDA Approval for New Dosage of Actonel
• Takeda Introduces Benet® for Osteoporosis Treatment
• Labtec Obtains Approval to Market Hormone Replacement Patch in Europe
• Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA
• Merck' s New Dosage of FOSAMAX PLUS D Gains FDA Approval
• Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug

8. MAJOR PLAYERS

• Eli Lilly and Company (US)
• F.Hoffmann-La Roche Ltd (Switzerland)
• Merck & Co., Inc. (US)
• Novartis AG (Switzerland)
• Novo Nordisk A/S (Denmark)
• Organon
• Procter & Gamble Pharmaceuticals Inc. (US)
• Sanofi-Aventis SA (France)
• Servier SA (France)
• Solvay Pharmaceuticals Inc. (US)
• Unigene Laboratories, Inc. (US)
• Wyeth (US)

9. GLOBAL MARKET ANALYTICS

10. THE UNITED STATES

• Industry Overview
• Osteoporosis in the US: An Insight
  • Osteoporosis - An Underserved Market?
• Osteoporosis Prescription Market
• Competitive Scenario
• Competitive Review by Segment
  • Bisphosphonates
• SERMs
• Calcitonins
  • PTH Therapy

11. JAPAN

12. EUROPE

• a. France
• b. Germany
• c. The United Kingdom
• d. Italy
• e. Spain
• f. Rest of Europe

13. REST OF WORLD

• Prevalence of Osteoporosis in Various Region-At a Glance
• Korea
• China

Related Reports